SynthesisBrain and behavior2025
Tenecteplase for Ischemic Stroke due to Large Vessel Occlusion at 4.5 to 24 Hours: A Meta-Analysis of Randomized Controlled Trials.
Synthesis in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Safety and efficacy of intravenous tenecteplase in patients with acute ischemic stroke in the extended time window: an updated meta-analysis.European journal of clinical pharmacology · 2026Pooled it
- Tenecteplase for Ischemic Stroke due to Large Vessel Occlusion at 4.5 to 24 Hours: A Meta-Analysis of Randomized Controlled Trials.Brain and behavior · 2025Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundWhether to use tenecteplase for acute ischemic stroke patients in the extended window has so far been little studied.
methodsIn this meta-analysis, we included all the randomized controlled trials comparing tenecteplase with control at 4.5 to 24 h after the last known well of acute ischemic stroke with large vessel occlusion. A systematic search was performed in PubMed, Web of Science, Embase, and Cochrane Central Register of Controlled Trials databases, up to 12th June, 2024. Our primary outcome was an excellent functional outcome with a modified Rankin scale score (mRS) of 0-1 at 90 days. Our safety outcomes included mRS 5-6 at 90 days, mortality within 90 days, symptomatic intracranial hemorrhage and parenchymal hematoma Type 2.
resultsUltimately, three studies involving 1198 patients were included in the pooled analysis, where tenecteplase exhibited a higher rate of mRS 0-1 at 90 days (OR, 1.36; 95%CI, 1.07-1.75; p = 0.01) and recanalization (OR, 3.30; 95%CI, 1.59-6.84; p = 0.001). For other outcomes, no significant differences were found between groups.
conclusionsThis meta-analysis of randomized controlled trials manifested that tenecteplase within a 4.5- to 24-h time window of large vessel occlusion stroke was superior to control for an excellent functional outcome (mRS 0-1) without safety concerns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.